Thank you Madrigal for your support on this FAQ Video Module.

In this expert update, Dr. Kimberly Brown, Associate Medical Director for Liver Transplantation at Henry Ford Hospital, discusses Resmetirom—the first and only FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). Resmetirom is a thyroid hormone receptor beta (THR-β) agonist that targets the liver to reduce triglyceride levels, leading to both NASH resolution and fibrosis regression. Dr. Brown highlights key clinical trial data showing significantly better outcomes with Resmetirom compared to placebo, including improvements in liver histology for patients with stage F2–F3 fibrosis. She addresses common questions about placebo response rates, side effect profiles (such as mild nausea and diarrhea), and the drug’s liver-specific mechanism of action with minimal systemic effects. Although not approved for patients with cirrhosis, ongoing trials may further expand its clinical use. Tune in to learn why Resmetirom represents a major step forward in treating MASH and how it fits into the evolving landscape of liver disease care.